Skip to main content

Ramucirumab Side Effects

Medically reviewed by Drugs.com. Last updated on Apr 22, 2023.

Applies to ramucirumab: intravenous solution.

Serious side effects of Ramucirumab

Along with its needed effects, ramucirumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ramucirumab:

More common

Less common

Incidence not known

Other side effects of Ramucirumab

Some side effects of ramucirumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ramucirumab: intravenous solution.

Gastrointestinal

Very common (10% or more): Diarrhea (32%), abdominal pain (29%), stomatitis (20%), mucosal inflammation, GI hemorrhage events (e.g., hemorrhage, diarrhea hemorrhage, gastric hemorrhage, hematemesis, hematochezia, hemorrhoidal hemorrhage, Mallory-Weiss syndrome, melaena, esophageal hemorrhage, rectal hemorrhage, upper GI hemorrhage) (10%)

Common (1% to 10%): Intestinal obstruction

Uncommon (0.1% to 1%): GI perforation[Ref]

Immunologic

Common (1% to 10%): Anti-ramucirumab antibodies

Uncommon (0.1% to 1%): Infusion related reactions, sepsis[Ref]

Dermatologic

Common (1% to 10%): Rash, Palmar-plantar erythrodysesthesia syndrome[Ref]

Hematologic

Very common (10% or more): Neutropenia (54%), leukopenia (34%), thrombocytopenia (13%)[Ref]

Nervous system

Common (1% to 10%): Headache

Rare (less than 0.1%): Reversible Posterior Leukoencephalopathy Syndrome (RPLS), hepatic encephalopathy[Ref]

Renal

Very common (10% or more): Proteinuria (17%)[Ref]

Cardiovascular

Very common (10% or more): Peripheral edema (25%), hypertension (25%)

Common (1% to 10%): Arterial thromboembolic events[Ref]

Metabolic

Very common (10% or more): Hypoalbuminemia (11%)

Common (1% to 10%): Hyponatremia, hypokalemia, hypoalbuminemia[Ref]

Other

Very common (10% or more): Fatigue/asthenia (57%), peripheral edema[Ref]

Respiratory

Very common (10% or more): Epistaxis (31%)[Ref]

Local

Common (1% to 10%): Infusion-related reactions[Ref]

Genitourinary

Very common (10% or more): Proteinuria[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Cyramza (ramucirumab). Eli Lilly and Company. 2014.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.